オハイオにおける血液がんの臨床試験
オハイオ内の拠点で、血液がんに関する22件の研究が参加者を募集しています。
オハイオ内の都市
公式研究テキスト（英語）
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Summa Health System - Akron Campus, Akron
- Cleveland Clinic Akron General, Akron
- Summa Health System - Barberton Campus, Barberton
- 他44件
被験者募集中観察研究健康なボランティア歓迎
40歳〜75歳 · 全性別 · 2026/10/02更新 · NCT05334069Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
- Cincinnati Children's Hospital Medical Center, Cincinnati
被験者募集中観察研究
0歳〜38歳 · 全性別 · 2026/10/01更新 · NCT06131801Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia
- Quetzal Site 8, Columbus
被験者募集中第3相
18歳〜71歳 · 全性別 · 2026/09/23更新 · NCT07504458Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
- Ohio State University Comprehensive Cancer Center, Columbus
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/23更新 · NCT03816345Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
- University of Cincinnati Medical Center, Cincinnati
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/21更新 · NCT07648264Collection of Research Data and Samples From Patients Treated With Immunotherapy to Study Its Side Effects
- Strecker Cancer Center-Belpre, Belpre
- Miami Valley Hospital South, Centerville
- Adena Regional Medical Center, Chillicothe
- 他27件
被験者募集中観察研究
全年齢 · 全性別 · 2026/09/17更新 · NCT04242095A Longitudinal Multi-Center Molecular Biomarker Discovery Registry for Patients With Hematologic Malignancies
- University of Cincinnati, Cincinnati
- OhioHealth Research Institute, Columbus
- Taylor Cancer Research Center, Maumee
被験者募集中観察研究
0歳以上 · 全性別 · 2026/09/02更新 · NCT07154823Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
- Ohio State University, Columbus
被験者募集中第3相
18歳以上 · 全性別 · 2026/08/20更新 · NCT07007312Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
- UH Seidman Cancer Center, Cleveland
被験者募集中第1相
18歳以上 · 全性別 · 2026/08/20更新 · NCT06001788A Phase 1 Study of IM-1021 in Participants With Advanced Cancer
- Gabrail Cancer Center, Canton
被験者募集中第1相
18歳以上 · 全性別 · 2026/08/10更新 · NCT06823167Weighted Blanket Use to Reduce Anxiety in Oncology Patients
- Ohio State University Comprehensive Cancer Center, Columbus
被験者募集中
18歳以上 · 全性別 · 2026/08/05更新 · NCT06089408A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
- Childrens Hospital Medical Center of Akron, Akron
- Cincinnati Children's Hospital, Cincinnati
- University Hospitals Case Medical Center, Cleveland
- 他3件
被験者募集中観察研究
全年齢 · 全性別 · 2026/07/06更新 · NCT01351545Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
- Cincinnati Children's Hospital Medical Center, Cincinnati
- University of Cincinnati, Cincinnati
- The Ohio State University, Columbus
被験者募集中第1相
13歳以上 · 全性別 · 2026/05/05更新 · NCT04771572CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
- Cleveland Clinic, Cleveland
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/04/16更新 · NCT03328078Vertebroplasty With Radiation Therapy for Spine Metastatic Cancer Patients With Indeterminate Lesion (SINS Criteria)
- Ohio State University Comprehensive Cancer Center, Columbus
被験者募集中
18歳以上 · 全性別 · 2026/04/09更新 · NCT05178472A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
- University Hospitals Cleveland Medical Center, Cleveland
- Cleveland Clinic Taussig Cancer Institute, Cleveland
- The James Cancer Hospital and Solove Research Institute, Columbus
被験者募集中第1相
18歳以上 · 全性別 · 2026/03/13更新 · NCT05735184Study to Evaluate the Pharmacokinetics and Safety of Pralatrexate in Patients With Advanced Solid Tumor or Hematological Malignancy and Either Normal Hepatic Function or Mild, Moderate, or Severe Hepatic Impairment
- Gabrail Cancer Center, Canton
被験者募集中第1相
18歳以上 · 全性別 · 2026/02/11更新 · NCT07036133A Study for Participants Previously Treated With Century Therapeutics Cellular Therapy Product
- University of Cincinnati Medical Center, Cincinnati
被験者募集中観察研究
18歳以上 · 全性別 · 2025/06/25更新 · NCT05768269IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
- University Hospitals Cleveland, Cleveland
被験者募集中第1/2相
18歳以上 · 全性別 · 2025/06/03更新 · NCT06119685αβT Cell/CD19+ B Cell Depletion for Alternative Donor Allogeneic Hematopoietic Cell Transplantation (HSCT)
- Nationwide Children's Hospital, Columbus
被験者募集中
30歳以下 · 全性別 · 2025/04/02更新 · NCT06082947Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
- Cincinnati Children's Hospital Medical Center, Cincinnati
- Rainbow Babies, Cleveland
- Nationwide Children's Hospital, Columbus
被験者募集中第1相
1歳〜21歳 · 全性別 · 2024/12/06更新 · NCT05476770Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies
- University of Cincinnati, Cincinnati
被験者募集中第1相
18歳以上 · 全性別 · 2024/11/15更新 · NCT06034275ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。